Research programme: anticancer monoclonal antibodies - Precision Biologics

Drug Profile

Research programme: anticancer monoclonal antibodies - Precision Biologics

Alternative Names: 16C3 antibody; 31.1 antibody; 31.1 monoclonal antibody; h16C3 monoclonal antibody; NEO-201; NEO-301; Sq-1; Sq-2

Latest Information Update: 07 May 2016

Price : $50

At a glance

  • Originator Neogenix Oncology
  • Developer National Cancer Institute (USA); Precision Biologics
  • Class Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Neoplasm antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Colorectal cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 17 Apr 2016 Pharmacodynamics data from a preclinical trial in Solid tumours released by Precision Biologics
  • 07 Apr 2016 Pharmacodynamics data from preclinical and in vitro studies in Cancer presented at the 107th Annual Meeting of American Association for Cancer Research (AACR-2016)
  • 21 Dec 2015 Precision Biologics establishes CRADA with National Cancer Institute for the development of monoclonal antibodies in Solid tumours
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top